New Customers Get 10% Off – Use Code: LUX10

Ipamorelin

5.0 Reviews

CAS: 170851-70-4NNC 26-0161

A synthetic pentapeptide composed of 5 amino acids that promotes growth hormone release by targeting the ghrelin receptor (GHSR-1a), while showing no significant impact on cortisol, ACTH, or prolactin levels in research settings. High-purity research peptide.

All products currently listed on this site are for research purposes only.

Original price was: $89.99.Current price is: $80.99.

2 Day FAST Shipping

99%+ Purity Tests

Ships from USA

USA Lab Tested

We accept :

Certificate of Analysis

Third Party Tested by Freedom Diagnostics

How Ipamorelin Works

The Science, Simplified

Highly Selective Ghrelin Receptor Agonism

Ipamorelin is a synthetic pentapeptide that binds with high affinity to the Growth Hormone Secretagogue Receptor (GHSR) in the brain, mimicking the natural hunger hormone ghrelin.
Key insight: Unlike older-generation GHRPs (such as GHRP-2 or GHRP-6), Ipamorelin is remarkably selective. It stimulates the pituitary gland to release Growth Hormone (GH) without triggering a corresponding rise in stress or reproductive hormones. Researchers observe a clean, pulse-like release of native growth hormone that closely mirrors the body’s natural circadian rhythm.

Preservation of Homeostasis (No Cortisol or Prolactin)

A major hurdle with early secretagogues was the accidental activation of other pituitary cells, leading to unwanted spikes in Cortisol (the stress hormone) and Prolactin.

Key insight: Ipamorelin completely bypasses this issue. Even at doses significantly above standard research thresholds, it demonstrates a near-zero impact on plasma cortisol or prolactin levels. This allows researchers to isolate and study the pure anabolic benefits of growth hormone—such as cellular repair, lipolysis, and collagen synthesis—without dealing with systemic hormonal interference.

Synergy with GHRH Analogs

While Ipamorelin can be studied as a standalone compound, it is structurally engineered to be evaluated alongside a Growth Hormone-Releasing Hormone (GHRH) analog like CJC-1295 or Sermorelin.

Key insight: When a GHRH (which tells the pituitary to produce more GH) is paired with a GHRP like Ipamorelin (which tells the pituitary to release a large pulse of GH), they work together in a highly predictable synergistic cascade. This dual-pathway approach maximizes total growth hormone output far more effectively than merely increasing the amount of a single peptide.

Research Handling Notes

What research literature describes

Ipamorelin was originally developed by Novo Nordisk and reached Phase II clinical trials, providing it with a highly documented characterization profile in the research literature.

🧿 Reagent Handling Guidance

12%

Store Lyophilized at -20°C

lab use

8%

Reconstitute for Lab Use

lab use

5%

Protect From Light

lab use

Safety Advantage:

Low Side-Effect Threshold

Compound Information

Technical specifications for each component

🔬 Molecular Profile

What Is Ipamorelin?

Type

Synthetic pentapeptide

CAS Number

170851-70-4

Molecular Weight

711.85 g/mol

Amino Acids

5

Sequence

Aib-His-D-2-Nal-D-Phe-Lys-NH2

Formula

C38H49N9O5

🧊 Storage Requirements

Stability Information

Lyophilized (Powder)

at -20°C

for up to 2 years

Reconstituted

2-8°C for 2-4 weeks

Handling Notes

Protect from direct light and moisture

📊 Physical Properties

Research Status

Classification

Growth Hormone Secretagogue (GHRP)

Development History

Novo Nordisk / Helsinn

Primary Research Goals

Growth Hormone Secretion, Muscle Physiology, Gut Motility, Metabolic Signaling

Regulatory Status

Investigational Research Chemical

Frequently Asked Questions

Common questions about Ipamorelin

They are natural teammates. CJC-1295 (a GHRH) acts as the amplifier by increasing the total amount of growth hormone your body creates. Ipamorelin acts as the trigger by forcing a massive release of that hormone. Using them together creates a synergistic effect that is vastly superior to using either one alone.
They are natural teammates. CJC-1295 (a GHRH) acts as the amplifier by increasing the total amount of growth hormone your body creates. Ipamorelin acts as the trigger by forcing a massive release of that hormone. Using them together creates a synergistic effect that is vastly superior to using either one alone.
Unlike older peptides like GHRP-2, which can cause significant fluid retention and puffiness due to cortisol spikes, Ipamorelin is highly selective. Fluid retention is rarely observed in research settings as long as standard laboratory handling protocols are followed.
Once administered in a laboratory setting, Ipamorelin triggers a sharp growth hormone spike that peaks around the 40-minute mark. The levels then gradually taper back down to baseline over the next 2 to 3 hours, cleanly avoiding long-term hormone elevation.
Ipamorelin successfully advanced through several human Phase I and Phase II clinical trials, displaying an excellent safety profile. However, it was never brought to the commercial market as a prescription drug, so it remains classified globally as an investigational research compound meant for laboratory evaluation.

Sources & References

Peer-reviewed research

Not for human consumption. This product is sold exclusively for research and educational purposes. It is not intended to diagnose, treat, cure, or prevent any disease.

All research data and findings presented on this page are sourced from peer-reviewed journals and official publications. They are provided for educational reference only and should not be interpreted as medical advice or product claims.

By purchasing this product, you confirm that you are a qualified researcher and will use it in accordance with all applicable laws and regulations.